A new partnership set out to develop and manufacture patient-accessible, place-of-care hematopoietic stem cell (HSC) cell and gene therapy workflows for diseases including sickle cell disease and beta thalassemia. The alliance combines Trenchant BioSystems’ AutoCell automated CGT manufacturing platform, UMass Chan Medical School’s blood stem cell expertise, and Caring Cross’s access-focused capabilities. The group plans to evaluate blood products for stem-cell separation and then build a lentiviral gene-transfer engineering platform, with the platform designed for scalability and operation in an ISO class 7 environment. A stated differentiator is microbubble separation, intended to reduce reliance on immunomagnetic bead-based workflows. The collaboration also includes an FDA-focused INTERACT meeting planned for the first quarter of 2027, followed by a clinical Phase I/II trial later in 2027. For biotech and clinical operations leaders, the headline is operational feasibility: reducing facility intensity and cost barriers is central to unlocking broader CGT access.